By increasing the levels and activity of GLP-1 and GIP, DPP-4 inhibitors stimulate insulin secretion, inhibit glucagon secretion, and improve glucose control, without causing hypoglycemia [2, 3]. The gene discussed is GCG; the disease is Hypoglycemia.